ScreenerHero

CRONCronos Group Inc. Common Share

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · thecronosgroup.com
3.310USDMkt Cap: 1.22B $P/E: 17.42

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporiz…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap1.22B $
Enterprise Value472.50M $
Revenue (TTM)179.09M $
Gross Profit62.76M $
Net Income (TTM)-9.45M $
Revenue/Share0.4720 USD
Last Price3.310 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees610
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA22717L1013
Valuation
P/E (Trailing)17.42
P/E (Forward)-82.75
PEG—
EV/EBITDA39.78
EV/Revenue2.64
P/S6.81
P/B1.15
EPS (TTM)0.19
EPS (Forward)-0.04
52W Range
3.22090% of range3.320
52W High3.320 USD
52W Low3.220 USD
Profitability
Gross Margin42.81%
Oper. Margin15.44%
EBITDA Margin6.63%
Profit Margin-6.44%
ROE-0.86%
ROA-0.79%
Growth
Revenue Growth58.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF25.87M $
CapEx (TTM)26.06M $
FCF Margin3.41%
FCF Yield0.50%
Net Debt-795.72M $
Net Debt/EBITDA-66.99
Balance Sheet
Debt/Equity0.00
Current Ratio16.18
Quick Ratio15.15
Book Value/Sh2.883 USD
Cash/Share2.163 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.544 USD
Upside (mean)-23.1%
Target Range2.544 USD – 2.544 USD
# Analysts1
Ownership
Shares Out.368.41M
Float186.99M
Insiders48.85%
Institutions15.48%
Short Interest
Short Ratio4.0d
Short % Float1.85%
Short % Out.0.92%
Shares Short3.42M
Short (prev mo.)3.14M
Technical
SMA 502.861 (+15.7%)
SMA 2002.688 (+23.1%)
Beta1.24
S&P 52W Chg19.18%
Avg Vol (30d)1.31M
Avg Vol (10d)1.35M
Technical Indicators
RSI (14)69.4
MACD0.1231
MACD Signal0.0983
MACD Hist.+0.0248
BB Upper3.389 USD
BB Middle3.027 USD
BB Lower2.666 USD
BB Width23.90%
ATR (14)0.1036 USD
Vol Ratio (20d)0.88x